XENT - Skepticism over AmeriSource acquisition speculation GSK upgraded following investor update and more in analyst action

LeoPatrizi/iStock via Getty Images AmerisourceBergen buying Parexel is unlikely AmerisourceBergen (ABC) potentially acquiring contract research organization Parexel -- as has been suggested in media reports -- is highly unlikely, according to BofA Securities. Analyst Michael Cherny notes that Amerisource just completed its acquisition of Alliance Healthcare, which will involve a multi-year integration. Parexel isn't quite a "fit" for Amerisource given that the former is more R&D focused and the latter is involved in manufacturer services businesses. Finally, the ~$9B deal would be sizable for Amerisource, whose market capitalization is ~$24B. GSK upgraded to hold following investor update Following yesterday's investor update and announcement it would spin off its consumer health unit, Deutsche Bank is upgrading shares to hold from sell with a price target of 1350p, up from 1300p. Analyst Emmanuel Papadakis said the company has set "reasonable credible" guidances to 2026. However, he says the company will "have many

For further details see:

Skepticism over AmeriSource acquisition speculation, GSK upgraded following investor update, and more in analyst action